buy & bph

If you know a bit of math, if you just bet on PEP11, read the following plz.

BUY has 700 million shares for 15%, BPH has 300 million for 17%.

BPH's SP should be 2.5 times higher than BUY!!! and BUY will have a SPP just a matter of time.

BUY's SP has no way to touch 5 baggers because of 700 million shares on issue. But BPH has the 5 baggers potential.

"BUY also has multiple other O&G assets that are about to fly."

BUY suffers loss from "other O&G assets " year by year, so I think these assets give BUY minus value!

BUY has only around 2 milllion cash left, after drilling one more well, it will ask for more funds by capital raising.

Should PEP 11 successful, who cares BUY's other hopeless assets?

We will only revalue the PEP11 groups by PEP11 potential.

Except PEP11, BPH's other projects:

BPH is commercialising a portfolio of Australian biomedical technologies emerging from collaborative research by leading universities, medical institutes and hospitals across Australia.Biomedical technologies in the commercialisation stage include:

? Diagnostic Array Systems; BacTrak (a faster
and more effective method for detecting infectious disease
? Cortical Dynamics? Brain Anaesthesia Response (BAR)Monitor; a device that measures a patient?s brain electrical activity (EEG) to indicate the response to drugs
administered during surgery
? HLS5 Tumour Suppress Gene; a genetic
marker for early and accurate cancer detection
? Microtubule drugs that target the tumour
vasculature

Molecular Discovery Systems (MDSystems), launched in 2006 and spun off from BPH in 2010, is a subsidiary of BPH for drug discovery and validation of biomarkers for disease, therapy and diagnostics.